WO1991012046A1 - Glaucoma valve - Google Patents

Glaucoma valve Download PDF

Info

Publication number
WO1991012046A1
WO1991012046A1 PCT/SE1991/000097 SE9100097W WO9112046A1 WO 1991012046 A1 WO1991012046 A1 WO 1991012046A1 SE 9100097 W SE9100097 W SE 9100097W WO 9112046 A1 WO9112046 A1 WO 9112046A1
Authority
WO
WIPO (PCT)
Prior art keywords
tube
eye
section
plate
valve
Prior art date
Application number
PCT/SE1991/000097
Other languages
French (fr)
Inventor
Jan-Ove Persson
Per-Arne GRANSTRÖM
Original Assignee
Atos Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atos Medical Ab filed Critical Atos Medical Ab
Publication of WO1991012046A1 publication Critical patent/WO1991012046A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/00781Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment

Definitions

  • the invention relates to a glaucoma valve, comprisin an elongated tube and a curved plate attached to one end the tube for connecting the interior of the eye to the su rounding tissue and draining a fluid from the interior of the eye to the surrounding tissue.
  • Glaucoma is an eye disease which, if not treated, gr dually leads to loss of vision.
  • the loss of vision is cau sed by the death and disappearance of the nerve fibers lo cated in the optical nerve and which normally transmit th information of vision from the retina of the eye to the v sual cortex in the brain.
  • the loss of the optical nerve f bers in connection with glaucoma is in turn caused by an abnormally high intraocular pressure in the eye.
  • aqueous humor In the interior of the eye there is constantly produ ced the so called aqueous humor, a clear liquid mainly co sisting of water.
  • the aqueus humor which is produced in the ciliary body of the eye behind the iris, flows throug the pupill towards the so called anterior chamber of the eye where the aqueous humor leaves the eye partly via a drainage system consisting of a number of fine pores, cal led the trabecular meshwork, partly via Schlemm's channel as well as the aqueous veins.
  • a balance between the production of aqueous humor and the outflow through the drainage system that causes the hy ⁇ drostatic pressure to reach a sufficiently high level in order to expand the tissues of the eye without injuring them. In connection with glaucoma this balance has been disturbed, usually caused by a too high flow resistance through the trabecular meshwork increasing whereby the pressure in the eye.
  • the treatment of glaucoma aims to lower the pressure of the liquid in the eye to a normal level. This can ofte be accomplished by means of different types of medication In several cases, however, medication only is not suffi ⁇ cient and a hole is then made through which aqueous humor can leak from the eye. Thus, there is accomplished an arti ficial drainage with a lowering of the fluid pressure of the eye as a consequense. The hole in the wall of the eye which is accomplished by surgery unfortunately often fills up again increasing the pressure. In order to secure a per manent drainage of aqueous humor from the eye some kind of valve or drainage tube is sometimes used which is inserted (implanted) into the eye by operation. The drainage device which are commercially available today have som disadvanta ges which are the cause of their rather limited use.
  • these drainage devices or so called glaucoma valves consist of a thin tube which is placed with one end in the anterior chamber and the other end on the surface o the sclerotic layer under what is called Tenon's capsule far up under the upper eyelid.
  • a plate or a so called sealant connected which is made of some plastic material.
  • the purpose of the plate is to increase the liquid absorbing surface where the outflo ⁇ wing aqueous humor meats the tissues on the outside of the eye.
  • some kind of pressure regulating valve device is connected to the upper end of the tube in order to accomplish a certain low back pressure in the tube thus preventing the pressure level in the eye from falling to zero.
  • Glaucoma valves available today exhibit among other things the following drawbacks:
  • the flow of aqueous humor often becomes to heavy and the pres ⁇ sure in the eye to low. This results in the bulging of the lense and the iris of the eye towards the back of the cor ⁇ nea and thereby the damaging of both the lense and the cornea. Furthermore, the too low pressure in the eye can cause the loosening of the choroid coat as it is called a the back of the eye with visual impairement as a conse ⁇ quense.
  • the scar tissue which is always formed around the up per end of the drainage tube and around the plate is in many cases so dense that it causes a too high flow resis ⁇ tance for the aqueous humor flowing out at the upper mout of the tube.
  • the intended lowering of the pressure in the eye is then not sufficient.
  • the liquid absorbing surface can be increased either by a larger surface of the implant or by a later implantation an additional valve.
  • the ope rating trauma increases more than if only one opertion an a smaller implant would have been enough.
  • the tubes of the now commercially available glaucoma valves have an outer diameter which is comparatively larg and they are also comparatively stiff so as to facilitate the implantation, usually the tube is implanted in such a way that it will for a certain distance run inside the sclerotic layer between its lamellas. If the tube is thic it will exert pressure on the tissue and thereby cause th gradual disapperance of sclerotic tissue. This sometimes results in the tube lying exposed on the surface of the eye.
  • One object of the present invention is to essentially overcome the above described problem with a glaucoma valve which in addition is very simple in its construction.
  • An other object of the invention is to provide a glau coma valve which by its shape is easy to implant and with which the implantation implies a low risk of damage. After the implantation the risk of inflammation, rejection or other damages shall also be low.
  • FIG. la is a cross sectional view of a healthy eye
  • FIG. lb is a cross sectional view of a part of a helthy eye in an enlarged scale
  • FIG. 2 is a cross sectional view of an eye with an im planted valve according to the invention
  • FIG. 3 is a side view of a part of a valve according to the invention.
  • FIG. 4 is a plan view from above of a part of a valve according to the invention.
  • FIG. 5 is a longitudinal section view of a tube accor ding to the invention
  • FIG. 6 is a cross sectional view taken along a line A A of the tube of FIG. 5.
  • FIG. la and lb show a helthy eye.
  • the eye consists of an almost spherical capsule with the cornea 1 in its front and the sclerotic layer 2 in its back. Both the cornea and the sclerotic layer are built up by rather solid tissues which are expanded by the liquid pressure from the interi of the eye. In this way the eye keeps its shape.
  • a short distance behind the cornea is the iris 3 located and behi this the lense 4.
  • the latter is kept in place by very thi fibers, the zonule of Zinn 5, in the ciliary body 6.
  • the musculature in the ciliary body can influence the tension in the zonula fibers and thus the shape of the lense.
  • the c liary body also has another function, that is to produce the aqueous humor, as it is called, which occurs in speci cells on the surface of the ciliary body (in the so calle ciliary epithelium) .
  • the produced aqueous humor moves for ward, bypass the lense and out through the pupil 7 to the anterior chamber 8 which is the liquid containing space s tuated between the back surface of the cornea and the fro surfaces of the iris/lense.
  • the aqueous humor leaves the anterior chamber of the eye via several very fine pores, jointly designated the trabecular meshwork 9, FIG. lb.
  • the vitreous body 1 Behind the lense of the eye lies the vitreous body 1 a clear jelly like liquid. Between the vitreous body and the sclerotic layer lies the retina 13 and the choroid co 14. From the retina emanate those nerve fibers which jointly form the optical nerve 15 and which transmit visu information from the eye to the brain. Within the front part of the eye the sclerotic layer is covered by a rela ⁇ tively thin, loosely constructed opaque film, what is cal ⁇ led conjuctiva 16. The conjuctiva does not cover the scle ⁇ rotic layer on the back of the eye but curves forward at 1 and instead covers the inside 18 of the eyelid.
  • a glaucoma valve From an incision in the surface of the sclerotic layer, at 20, a channel 21 is prepared withi the sclerotic connective tissue opening into the anterior chamber 8 of the eye. Into the channel is introduced a fin tube 22, one end thereof opening in the chamber of the eye The other end of the tube is connected to a plate 23 which in the embodiment shown is constructed of PMMA and in whic the tube ends. The plate will lie on the surface of the ey (the sclerotic layer 2) under Tenon's capsule 19. The plat increases the liquid absorbing surface of the surrounding tissue where the aqueous humor flows out at the upper end of the tube.
  • the plate 23 is more clearly evident.
  • the plate is cir- cular, slightly vaulted and constructed of PMMA.
  • Other em ⁇ bodiments and materials are, however, also possible.
  • both the tube and the plate can be constructed of the same material (silicon rubber) and then in one piece.
  • the plate is preferrably heparinized and coated with layer of titanium.
  • the thickness of the titanium layer should lay within the interval 200-1000 A (200*10" 10 m- 1000*" 10 m) .
  • the purpose of the surface coating with hepar or titanium is too drastically reduce the tissue reaction around the plate always arising from implantation of fo ⁇ reign material on the surface of the eye and which causes scar formation and thus detoriated absorption of the aqueous humor. By this measure a sufficient amount of aqueous humor flow is secured without the necessity of su a large surface of the plate.
  • the tube has inner diameter i less than that of prior art glaucoma valves.
  • the inner diameter is only 0.20 mm.
  • the inner diameter should lie within the interval 0.15-0. mm and the inner diameter should not exceed 0.25 mm.
  • the length of the glaucoma valve according to the invention will lie within the inte val 15-20 mm. Together with the chosen inner diameter thi length results in a desired restriction effect of the valve. If another length is chosen the inner diameter is adapted in order to keep the desired contracting effect.
  • a length of 10 mm a suitable inner diameter is about 0.18 mm.
  • the restriction effect is available immediately after the implantation. According to the invention only a part the tube has to be constructed with the above specified d mensions in order to obtain the desired restriction effec This part of the tube, at least, has a closed interior en velope surface so that no abduction of aqueous humor will occur there. The remaining parts of the tube are construc ted with greater dimensions in order not to contribute to the restriction.
  • the desired restriction effect correspond to a counter pressure for the flow of aqueous humor of between 1 mm Hg and 15 mm Hg. At a high counter pressure from the tissue which surrounds the plate 23 the counter pressure in that part should be lower.
  • the plate 23 is constructed with an inner channel which in one end recieves the tube and the other end ends in the surface of the plate, for example in the center of the plate.
  • the channel comprises a part with the above men tioned dimensions achieving the desired restricting effect.
  • the channel is spiral shaped and ends in the center of the plate and in another alternative embodi ⁇ ment the channel is constructed as a coil of desired lengt with several parts running parallell.
  • the lower end is bevelled.
  • the tube is implanted with the lower be ⁇ velled edge positioned so that the opening will point obliquely ahead downwards towards the center of the cornea. This will eliminate the risk of obstructing the lower ope ⁇ ning of the tube by the iris, if this should contact the lower end of the tube.
  • FIG.6 which is a cross section along the line A- of FIG. 5 , another feature of the tube is shown. Since the cross section of the tube is elliptic several important characteristics are obtained.
  • the sclerotic layer is con ⁇ structed of several thin lamella which are arranged in pa ⁇ rallell both between themselves and relative to the surfac of the sclerotic layer.
  • the individual lamella have co pa- ratively high strength but are loosely connected with each other.
  • This construction of the sclerotic layer results in an always flat cross section of the channel prepared for implantation.
  • An elliptic tube according to the invention adheres thoroughly against the channel in the sclerotic layer in order to obtain a good sealing between the tube and the channel.
  • a leakage at the side of the tube re sults in an uncontrolled outflow of aqueous humor and thu a too low pressure in the eye with the risk of permanent damages to the eye as a consequense.
  • An additional advantage of a tube elliptic in cross section is that the tube becomes more rigid compared with tube circular in cross section and is thus more easier to introduce in the channel prepared.
  • a good sealing between the tube and the sclerotic layer can also be achieved with a circular tube but in or der to obtain a good sealing the tube will then excert a comparatively high pressure towards the outer and inner surfaces of the sclerotic layer.
  • the increased mechanical pressure which is excerted by a circular tube on the scle rotic tissue leads to a gradual breakdown of the tissue.
  • the result is that until now available circular tubes of glaucoma valves sometimes are forced up and remain naked the front surface of the eye. This risk is considerably lesser with a tube according to the invention.
  • the risk o irritating the surrounding tissue is also considerably re swiped both in connection with the implantation and after ⁇ wards during the life span of the implantate.
  • the inside contoure of the tube is circular in the embodiment shown but this shape can be varied within the scope of the inve tion.

Abstract

The invention relates to a glaucoma valve, comprising an elongated tube (22) and a curved plate (23) attached to one end of said tube (22) for connecting the interior of the eye to surrounding tissue and draining a liquid flow from the interior of the eye to said surrounding tissue. A channel enclosed in said tube and said plate is formed with a section having a closed interior envelope surface, the inner diameter and the length of said section being adjusted to accomplish the desired restriction of said liquid flow.

Description

GLAUCOMA VALVE
The invention relates to a glaucoma valve, comprisin an elongated tube and a curved plate attached to one end the tube for connecting the interior of the eye to the su rounding tissue and draining a fluid from the interior of the eye to the surrounding tissue.
Glaucoma is an eye disease which, if not treated, gr dually leads to loss of vision. The loss of vision is cau sed by the death and disappearance of the nerve fibers lo cated in the optical nerve and which normally transmit th information of vision from the retina of the eye to the v sual cortex in the brain. The loss of the optical nerve f bers in connection with glaucoma is in turn caused by an abnormally high intraocular pressure in the eye.
In the interior of the eye there is constantly produ ced the so called aqueous humor, a clear liquid mainly co sisting of water. The aqueus humor, which is produced in the ciliary body of the eye behind the iris, flows throug the pupill towards the so called anterior chamber of the eye where the aqueous humor leaves the eye partly via a drainage system consisting of a number of fine pores, cal led the trabecular meshwork, partly via Schlemm's channel as well as the aqueous veins. In a normal eye there exist a balance between the production of aqueous humor and the outflow through the drainage system that causes the hy¬ drostatic pressure to reach a sufficiently high level in order to expand the tissues of the eye without injuring them. In connection with glaucoma this balance has been disturbed, usually caused by a too high flow resistance through the trabecular meshwork increasing whereby the pressure in the eye.
The treatment of glaucoma aims to lower the pressure of the liquid in the eye to a normal level. This can ofte be accomplished by means of different types of medication In several cases, however, medication only is not suffi¬ cient and a hole is then made through which aqueous humor can leak from the eye. Thus, there is accomplished an arti ficial drainage with a lowering of the fluid pressure of the eye as a consequense. The hole in the wall of the eye which is accomplished by surgery unfortunately often fills up again increasing the pressure. In order to secure a per manent drainage of aqueous humor from the eye some kind of valve or drainage tube is sometimes used which is inserted (implanted) into the eye by operation. The drainage device which are commercially available today have som disadvanta ges which are the cause of their rather limited use.
Usually these drainage devices or so called glaucoma valves consist of a thin tube which is placed with one end in the anterior chamber and the other end on the surface o the sclerotic layer under what is called Tenon's capsule far up under the upper eyelid. At the upper end of the tub is often a plate or a so called sealant connected which is made of some plastic material. The purpose of the plate is to increase the liquid absorbing surface where the outflo¬ wing aqueous humor meats the tissues on the outside of the eye. In some cases some kind of pressure regulating valve device is connected to the upper end of the tube in order to accomplish a certain low back pressure in the tube thus preventing the pressure level in the eye from falling to zero.
Glaucoma valves available today exhibit among other things the following drawbacks:
During one or some weeks after the implantation the flow of aqueous humor often becomes to heavy and the pres¬ sure in the eye to low. This results in the bulging of the lense and the iris of the eye towards the back of the cor¬ nea and thereby the damaging of both the lense and the cornea. Furthermore, the too low pressure in the eye can cause the loosening of the choroid coat as it is called a the back of the eye with visual impairement as a conse¬ quense.
Some weeks after the operation a fibrous scar tissue is often formed around the upper end of the tube and arou the plate and this scar tissue then causes a hindering ef fect on the flow of aqueous humor partly increasing the pressure in the eye . The liquid space between the lense/iris and the choroid coat is then regenerated and t loosening of the choroid coat usually abates. When this happens, however, permanent damages to the eye may alread have appeared, which are caused by the initially too low pressure.
The scar tissue which is always formed around the up per end of the drainage tube and around the plate is in many cases so dense that it causes a too high flow resis¬ tance for the aqueous humor flowing out at the upper mout of the tube. The intended lowering of the pressure in the eye is then not sufficient. In order to meet this problem the liquid absorbing surface can be increased either by a larger surface of the implant or by a later implantation an additional valve. However, in both these cases the ope rating trauma increases more than if only one opertion an a smaller implant would have been enough. The tubes of the now commercially available glaucoma valves have an outer diameter which is comparatively larg and they are also comparatively stiff so as to facilitate the implantation, usually the tube is implanted in such a way that it will for a certain distance run inside the sclerotic layer between its lamellas. If the tube is thic it will exert pressure on the tissue and thereby cause th gradual disapperance of sclerotic tissue. This sometimes results in the tube lying exposed on the surface of the eye. This is a very serious condition that calls for an i mediate operative measure in order to prevent a serious da mage to the eye by the leakage of aqueous humor at the sid of the tube or by the spreading of bacteria to the interio of the eye with a serious infection as a consequense. One object of the present invention is to essentially overcome the above described problem with a glaucoma valve which in addition is very simple in its construction.
An other object of the invention is to provide a glau coma valve which by its shape is easy to implant and with which the implantation implies a low risk of damage. After the implantation the risk of inflammation, rejection or other damages shall also be low.
In order to achieve the above mentioned objects the glaucoma valve according to the invention has obtained the characterizing features of claim 1.
The invention will now be further explained in more detail below by means of two embodiments reference being made to the accompanying drawings, in which
FIG. la is a cross sectional view of a healthy eye, FIG. lb is a cross sectional view of a part of a helthy eye in an enlarged scale,
FIG. 2 is a cross sectional view of an eye with an im planted valve according to the invention,
FIG. 3 is a side view of a part of a valve according to the invention,
FIG. 4 is a plan view from above of a part of a valve according to the invention,
FIG. 5 is a longitudinal section view of a tube accor ding to the invention, and FIG. 6 is a cross sectional view taken along a line A A of the tube of FIG. 5.
FIG. la and lb show a helthy eye. The eye consists of an almost spherical capsule with the cornea 1 in its front and the sclerotic layer 2 in its back. Both the cornea and the sclerotic layer are built up by rather solid tissues which are expanded by the liquid pressure from the interi of the eye. In this way the eye keeps its shape. A short distance behind the cornea is the iris 3 located and behi this the lense 4. The latter is kept in place by very thi fibers, the zonule of Zinn 5, in the ciliary body 6. The musculature in the ciliary body can influence the tension in the zonula fibers and thus the shape of the lense. Thi is the cause of the adjustment of the eye for short dista ces (accomodation) which takes place with younger and middle aged individuals at work close to an object. The c liary body also has another function, that is to produce the aqueous humor, as it is called, which occurs in speci cells on the surface of the ciliary body (in the so calle ciliary epithelium) . The produced aqueous humor moves for ward, bypass the lense and out through the pupil 7 to the anterior chamber 8 which is the liquid containing space s tuated between the back surface of the cornea and the fro surfaces of the iris/lense. The aqueous humor leaves the anterior chamber of the eye via several very fine pores, jointly designated the trabecular meshwork 9, FIG. lb. These pores are arranged along a circular band circumfere tially located in the surface layer of the back of the co nea. When the aqueuos humor has passed the trabecular mes work it reaches a circular channel, Schlemm's channel 10 the periphery of the cornea and from there passes on via the aqueous veins 11, as they are called, out into the ge neral blood circulation.
Behind the lense of the eye lies the vitreous body 1 a clear jelly like liquid. Between the vitreous body and the sclerotic layer lies the retina 13 and the choroid co 14. From the retina emanate those nerve fibers which jointly form the optical nerve 15 and which transmit visu information from the eye to the brain. Within the front part of the eye the sclerotic layer is covered by a rela¬ tively thin, loosely constructed opaque film, what is cal¬ led conjuctiva 16. The conjuctiva does not cover the scle¬ rotic layer on the back of the eye but curves forward at 1 and instead covers the inside 18 of the eyelid. From the area where the conjuctiva "turns" (at 17), and backwards, the surface of the sclerotic layer is covered by a loose, fibrous capsule of connective tissue, called Tenon's cap¬ sule 19. The most usual form of glaucoma is when the fine pore in the trabecular meshwork is totally or partly clogged leading to an increase of the pressure in the eye and the damage of the optical nerve.
With reference to FIG. 2 the implantation of the de- vice according to the invention, a glaucoma valve, will no be further described. From an incision in the surface of the sclerotic layer, at 20, a channel 21 is prepared withi the sclerotic connective tissue opening into the anterior chamber 8 of the eye. Into the channel is introduced a fin tube 22, one end thereof opening in the chamber of the eye The other end of the tube is connected to a plate 23 which in the embodiment shown is constructed of PMMA and in whic the tube ends. The plate will lie on the surface of the ey (the sclerotic layer 2) under Tenon's capsule 19. The plat increases the liquid absorbing surface of the surrounding tissue where the aqueous humor flows out at the upper end of the tube.
From FIG. 3 and 4 the design of the plate 23 is more clearly evident. In the shown embodiment the plate is cir- cular, slightly vaulted and constructed of PMMA. Other em¬ bodiments and materials are, however, also possible. For example both the tube and the plate can be constructed of the same material (silicon rubber) and then in one piece. The plate is preferrably heparinized and coated with layer of titanium. The thickness of the titanium layer should lay within the interval 200-1000 A (200*10"10m- 1000*"10m) . The purpose of the surface coating with hepar or titanium is too drastically reduce the tissue reaction around the plate always arising from implantation of fo¬ reign material on the surface of the eye and which causes scar formation and thus detoriated absorption of the aqueous humor. By this measure a sufficient amount of aqueous humor flow is secured without the necessity of su a large surface of the plate.
One feature of the tube is that its inner diameter i less than that of prior art glaucoma valves. In a preferr embodiment the inner diameter is only 0.20 mm. Preferrabl the inner diameter should lie within the interval 0.15-0. mm and the inner diameter should not exceed 0.25 mm. By t choice of inner diameter in this interval an effective drainage of aqueous humor is ensured without the risk of too high flow with a too large pressure drop in the chamb of the eye as a consequense. The length of the glaucoma valve according to the invention will lie within the inte val 15-20 mm. Together with the chosen inner diameter thi length results in a desired restriction effect of the valve. If another length is chosen the inner diameter is adapted in order to keep the desired contracting effect. a length of 10 mm a suitable inner diameter is about 0.18 mm. The restriction effect is available immediately after the implantation. According to the invention only a part the tube has to be constructed with the above specified d mensions in order to obtain the desired restriction effec This part of the tube, at least, has a closed interior en velope surface so that no abduction of aqueous humor will occur there. The remaining parts of the tube are construc ted with greater dimensions in order not to contribute to the restriction. The desired restriction effect correspond to a counter pressure for the flow of aqueous humor of between 1 mm Hg and 15 mm Hg. At a high counter pressure from the tissue which surrounds the plate 23 the counter pressure in that part should be lower.
In an alternative, not shown, embodiment of the inven tion the plate 23 is constructed with an inner channel which in one end recieves the tube and the other end ends in the surface of the plate, for example in the center of the plate. The channel comprises a part with the above men tioned dimensions achieving the desired restricting effect. In one embodiment the channel is spiral shaped and ends in the center of the plate and in another alternative embodi¬ ment the channel is constructed as a coil of desired lengt with several parts running parallell.
An additional feature of the tube is that the lower end is bevelled. The tube is implanted with the lower be¬ velled edge positioned so that the opening will point obliquely ahead downwards towards the center of the cornea. This will eliminate the risk of obstructing the lower ope¬ ning of the tube by the iris, if this should contact the lower end of the tube.
From FIG.6 which is a cross section along the line A- of FIG. 5 , another feature of the tube is shown. Since the cross section of the tube is elliptic several important characteristics are obtained. The sclerotic layer is con¬ structed of several thin lamella which are arranged in pa¬ rallell both between themselves and relative to the surfac of the sclerotic layer. The individual lamella have co pa- ratively high strength but are loosely connected with each other. This construction of the sclerotic layer results in an always flat cross section of the channel prepared for implantation. An elliptic tube according to the invention adheres thoroughly against the channel in the sclerotic layer in order to obtain a good sealing between the tube and the channel. Thereby the risk of leakage of aqueous humor alo the tube is reduced. A leakage at the side of the tube re sults in an uncontrolled outflow of aqueous humor and thu a too low pressure in the eye with the risk of permanent damages to the eye as a consequense.
An additional advantage of a tube elliptic in cross section is that the tube becomes more rigid compared with tube circular in cross section and is thus more easier to introduce in the channel prepared.
A good sealing between the tube and the sclerotic layer can also be achieved with a circular tube but in or der to obtain a good sealing the tube will then excert a comparatively high pressure towards the outer and inner surfaces of the sclerotic layer. The increased mechanical pressure which is excerted by a circular tube on the scle rotic tissue leads to a gradual breakdown of the tissue. The result is that until now available circular tubes of glaucoma valves sometimes are forced up and remain naked the front surface of the eye. This risk is considerably lesser with a tube according to the invention. The risk o irritating the surrounding tissue is also considerably re duced both in connection with the implantation and after¬ wards during the life span of the implantate. The inside contoure of the tube is circular in the embodiment shown but this shape can be varied within the scope of the inve tion. The very simple construction of the glaucoma valve r sults in a very long working life of the valve but a very small risk of complications.

Claims

1. Glaucoma valve, comprising an elongated tube (22) and a curved plate (23) attached to one end of said tube (22) for connecting the interior of the eye to surrounding tissue and draining a liquid flow from the interior of the eye to said surrounding tissue, c h a r a c t e r i z e d by a channel enclosed in said tube (22) and said plate (23), said channel including a section having a closed interior envelope surface, said inner diameter and said length of said section being adjusted to accomplish the desired re¬ striction of said liquid flow.
2. Glaucoma valve as in claim 1, c h a r a c t e r i z e d by said inner diameter of said section being less than or equal to 0.25 mm and said length of said section being cho¬ sen in order to obtain a counter pressure between 1 mm Hg and 15 mm Hg.
3. Glaucoma valve as in claim 1, c h a r a c t e r i z e d by said inner diameter of said section being within the in- terval 0.15-0.21 mm and said length of said section being chosen in order to obtain a counter pressure between 1 mm Hg and 15 mm Hg.
4. Glaucoma valve as in claim 1, c h a r a c t e r i z e d by said inner diameter of said section being 0.20 mm and said length of said section being chosen in order to obtain a counter pressure between 1 mm Hg and 15 mm Hg.
5. Glaucoma valve as in any preceeding claim c h a r a c ¬ t e r i z e d by said section being constructed as a channel in said plate (23).
6. Glaucoma valve as in any preceeding claim c h a r a c ¬ t e r i s e d by said tube (22) being constructed elliptical in cross section.
7. Glaucoma valve as in any preceeding claim c h a r a c ¬ t e r i z e d by the free end of said tube (22) being bevelled.
8. Glacoma valve as in any preceeding claim c h a r a c ¬ t e r i z e d by said plate (23) being heparinized.
9. Glaucoma valve as in any of claims 1-7, c h a r a c ¬ t e r i z e d by said plate (23) being coated with a titanium layer.
10. Glaucoma valve as in any of claims 1-7, c h r c ¬ t e r i z e d by said plate (21) being made of titanium.
11. Glaucoma valve as in any of claims 1-7, c h a r a c ¬ t e r i z e d by said plate (23) being made of silicon an constructed in one piece with said tube (22).
12. Glaucoma valve as in any of claims 1-7, c h a r a c ¬ t e r i z e d by said plate being made of a rigid polymer material and connected with said tube (22).
PCT/SE1991/000097 1990-02-12 1991-02-12 Glaucoma valve WO1991012046A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9000491A SE9000491L (en) 1990-02-12 1990-02-12 GLAUCOMA VALVE
SE9000491-2 1990-02-12

Publications (1)

Publication Number Publication Date
WO1991012046A1 true WO1991012046A1 (en) 1991-08-22

Family

ID=20378527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1991/000097 WO1991012046A1 (en) 1990-02-12 1991-02-12 Glaucoma valve

Country Status (3)

Country Link
EP (1) EP0515489A1 (en)
SE (1) SE9000491L (en)
WO (1) WO1991012046A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013234A1 (en) * 1992-12-17 1994-06-23 Michael Andrew Coote Implant device and method for treatment of glaucoma
US5370641A (en) * 1992-05-22 1994-12-06 O'donnell, Jr.; Francis E. Laser trabeculodissection
WO1996003944A1 (en) * 1994-08-01 1996-02-15 Iovision, Inc. Glaucoma implant with a temporary flow-restricting seal
GB2296663A (en) * 1995-01-03 1996-07-10 Ahmed Salih Mahmud Drainage device for alleviating excess ophthalmic fluid pressure
US5558629A (en) * 1990-05-31 1996-09-24 Iovision, Inc. Glaucoma implant
WO1998030181A1 (en) * 1997-01-10 1998-07-16 University College London Device for use in the eye
WO1999038470A2 (en) * 1998-01-29 1999-08-05 David Pyam Soltanpour Method and apparatus for controlling intraocular pressure
US6162193A (en) * 1995-03-16 2000-12-19 Forskarpatent I Uppsala Ab Ultrasound probe
WO2010111528A3 (en) * 2009-03-26 2011-03-24 Abbott Medical Optics Inc. Glaucoma shunts with flow management and improved surgical performance
US8353856B2 (en) 2008-11-05 2013-01-15 Abbott Medical Optics Inc. Glaucoma drainage shunts and methods of use
US8945038B2 (en) 2003-05-05 2015-02-03 Transcend Medical, Inc. Internal shunt and method for treating glaucoma
US9084662B2 (en) 2006-01-17 2015-07-21 Transcend Medical, Inc. Drug delivery treatment device
US9089392B2 (en) 2009-12-23 2015-07-28 Transcend Medical, Inc. Drug delivery devices and methods
US9155656B2 (en) 2012-04-24 2015-10-13 Transcend Medical, Inc. Delivery system for ocular implant
US9351873B2 (en) 2003-11-14 2016-05-31 Transcend Medical, Inc. Ocular pressure regulation
US9398977B2 (en) 2006-01-17 2016-07-26 Transcend Medical, Inc. Glaucoma treatment device
US9480598B2 (en) 2012-09-17 2016-11-01 Novartis Ag Expanding ocular implant devices and methods
US9585789B2 (en) 2007-07-17 2017-03-07 Novartis Ag Ocular implant with hydrogel expansion capabilities
US9763829B2 (en) 2012-11-14 2017-09-19 Novartis Ag Flow promoting ocular implant
US9763828B2 (en) 2009-01-28 2017-09-19 Novartis Ag Ocular implant with stiffness qualities, methods of implantation and system
US9987163B2 (en) 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances
US10016301B2 (en) 2008-06-25 2018-07-10 Novartis Ag Ocular implant with shape change capabilities
US10085633B2 (en) 2012-04-19 2018-10-02 Novartis Ag Direct visualization system for glaucoma treatment
US11672701B2 (en) 2018-10-25 2023-06-13 Amo Groningen B.V. Bleb control glaucoma shunts

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3159161A (en) * 1962-11-14 1964-12-01 Ness Richard Alton Fistulizing canaliculus
GB2172203A (en) * 1985-03-14 1986-09-17 Univ Manchester A urethral catheter
US4750901A (en) * 1986-03-07 1988-06-14 Molteno Anthony C B Implant for drainage of aqueous humour
US4787885A (en) * 1984-04-06 1988-11-29 Binder Perry S Hydrogel seton
US4826478A (en) * 1986-06-23 1989-05-02 Stanley Schocket Anterior chamber tube shunt to an encircling band, and related surgical procedure
US4886488A (en) * 1987-08-06 1989-12-12 White Thomas C Glaucoma drainage the lacrimal system and method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3159161A (en) * 1962-11-14 1964-12-01 Ness Richard Alton Fistulizing canaliculus
US4787885A (en) * 1984-04-06 1988-11-29 Binder Perry S Hydrogel seton
GB2172203A (en) * 1985-03-14 1986-09-17 Univ Manchester A urethral catheter
US4750901A (en) * 1986-03-07 1988-06-14 Molteno Anthony C B Implant for drainage of aqueous humour
US4826478A (en) * 1986-06-23 1989-05-02 Stanley Schocket Anterior chamber tube shunt to an encircling band, and related surgical procedure
US4886488A (en) * 1987-08-06 1989-12-12 White Thomas C Glaucoma drainage the lacrimal system and method

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558629A (en) * 1990-05-31 1996-09-24 Iovision, Inc. Glaucoma implant
US5370641A (en) * 1992-05-22 1994-12-06 O'donnell, Jr.; Francis E. Laser trabeculodissection
WO1994013234A1 (en) * 1992-12-17 1994-06-23 Michael Andrew Coote Implant device and method for treatment of glaucoma
WO1996003944A1 (en) * 1994-08-01 1996-02-15 Iovision, Inc. Glaucoma implant with a temporary flow-restricting seal
GB2296663A (en) * 1995-01-03 1996-07-10 Ahmed Salih Mahmud Drainage device for alleviating excess ophthalmic fluid pressure
US6162193A (en) * 1995-03-16 2000-12-19 Forskarpatent I Uppsala Ab Ultrasound probe
WO1998030181A1 (en) * 1997-01-10 1998-07-16 University College London Device for use in the eye
WO1999038470A2 (en) * 1998-01-29 1999-08-05 David Pyam Soltanpour Method and apparatus for controlling intraocular pressure
WO1999038470A3 (en) * 1998-01-29 1999-10-07 David Pyam Soltanpour Method and apparatus for controlling intraocular pressure
US9844462B2 (en) 2003-05-05 2017-12-19 Novartis Ag Internal shunt and method for treating glaucoma
US8945038B2 (en) 2003-05-05 2015-02-03 Transcend Medical, Inc. Internal shunt and method for treating glaucoma
US9351873B2 (en) 2003-11-14 2016-05-31 Transcend Medical, Inc. Ocular pressure regulation
US10226380B2 (en) 2003-11-14 2019-03-12 Novartis Ag Ocular pressure regulation
US10905590B2 (en) 2006-01-17 2021-02-02 Alcon Inc. Glaucoma treatment device
US9084662B2 (en) 2006-01-17 2015-07-21 Transcend Medical, Inc. Drug delivery treatment device
US9789000B2 (en) 2006-01-17 2017-10-17 Novartis Ag Glaucoma treatment device
US9668917B2 (en) 2006-01-17 2017-06-06 Novartis Ag Drug delivery treatment device
US11786402B2 (en) 2006-01-17 2023-10-17 Alcon Inc. Glaucoma treatment device
US9398977B2 (en) 2006-01-17 2016-07-26 Transcend Medical, Inc. Glaucoma treatment device
US9421130B2 (en) 2006-01-17 2016-08-23 Novartis Ag. Glaucoma treatment device
US9585789B2 (en) 2007-07-17 2017-03-07 Novartis Ag Ocular implant with hydrogel expansion capabilities
US10016301B2 (en) 2008-06-25 2018-07-10 Novartis Ag Ocular implant with shape change capabilities
US9468558B2 (en) 2008-11-05 2016-10-18 Abbott Medical Optics Inc. Glaucoma drainage shunts and methods of use
US8920357B2 (en) 2008-11-05 2014-12-30 Abbott Medical Optics Inc. Glaucoma drainage shunts and methods of use
US8353856B2 (en) 2008-11-05 2013-01-15 Abbott Medical Optics Inc. Glaucoma drainage shunts and methods of use
US10492948B2 (en) 2008-11-05 2019-12-03 Johnson & Johnson Surgical Vision, Inc. Glaucoma drainage shunts and methods of use
US9763828B2 (en) 2009-01-28 2017-09-19 Novartis Ag Ocular implant with stiffness qualities, methods of implantation and system
US10531983B2 (en) 2009-01-28 2020-01-14 Novartis Ag Ocular implant with stiffness qualities, methods of implantation and system
US11839571B2 (en) 2009-01-28 2023-12-12 Alcon Inc. Ocular implant with stiffness qualities, methods of implantation and system
US11344448B2 (en) 2009-01-28 2022-05-31 Alcon Inc. Ocular implant with stiffness qualities, methods of implantation and system
WO2010111528A3 (en) * 2009-03-26 2011-03-24 Abbott Medical Optics Inc. Glaucoma shunts with flow management and improved surgical performance
AU2010229789B2 (en) * 2009-03-26 2014-11-13 Johnson & Johnson Surgical Vision, Inc. Glaucoma shunts with flow management and improved surgical performance
US8702639B2 (en) 2009-03-26 2014-04-22 Abbott Medical Optics Inc. Glaucoma shunts with flow management and improved surgical performance
US9089392B2 (en) 2009-12-23 2015-07-28 Transcend Medical, Inc. Drug delivery devices and methods
US9549846B2 (en) 2009-12-23 2017-01-24 Novartis Ag Drug delivery devices and methods
US10085633B2 (en) 2012-04-19 2018-10-02 Novartis Ag Direct visualization system for glaucoma treatment
US9907697B2 (en) 2012-04-24 2018-03-06 Novartis Ag Delivery system for ocular implant
US9241832B2 (en) 2012-04-24 2016-01-26 Transcend Medical, Inc. Delivery system for ocular implant
US10912676B2 (en) 2012-04-24 2021-02-09 Alcon Inc. Delivery system for ocular implant
US9155656B2 (en) 2012-04-24 2015-10-13 Transcend Medical, Inc. Delivery system for ocular implant
US9480598B2 (en) 2012-09-17 2016-11-01 Novartis Ag Expanding ocular implant devices and methods
US9763829B2 (en) 2012-11-14 2017-09-19 Novartis Ag Flow promoting ocular implant
US9987163B2 (en) 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances
US11672701B2 (en) 2018-10-25 2023-06-13 Amo Groningen B.V. Bleb control glaucoma shunts

Also Published As

Publication number Publication date
SE9000491D0 (en) 1990-02-12
SE9000491L (en) 1991-08-13
EP0515489A1 (en) 1992-12-02

Similar Documents

Publication Publication Date Title
WO1991012046A1 (en) Glaucoma valve
EP0532654B1 (en) Glaucoma implant
US10492948B2 (en) Glaucoma drainage shunts and methods of use
US5879319A (en) Sclerotomy implant
US4886488A (en) Glaucoma drainage the lacrimal system and method
US4729761A (en) Tissue-implantable, fluid-dissipating device
US20030236483A1 (en) Dual drainage ocular shunt for glaucoma
CA1295907C (en) Glaucoma drainage in the lacrimal system
US4604087A (en) Aqueous humor drainage device
US7357778B2 (en) Aqueous drainage and flow regulating implant
US5397300A (en) Glaucoma implant
EP0773759B1 (en) Glaucoma implant with a temporary flow-restricting seal
US4787885A (en) Hydrogel seton
EP0102747B1 (en) Ocular pressure relief device
US4521210A (en) Eye implant for relieving glaucoma, and device and method for use therewith
EP0168201B1 (en) Aqueous humour drainage device
US11779489B2 (en) Apparatus for treating excess intraocular fluid having an elastic membrane
US20210196517A1 (en) Apparatus for treating excess intraocular fluid having an elastic membrane
US20190046356A1 (en) Methods Materials Assemblies Apparatuses and Implants for Surgical Reduction of Intraocular Pressure to Suprachoidal Space Ab Externo and Subconjunctival Space
US20180078416A1 (en) Inlet tube protector for glaucoma shunts
WO1993020783A1 (en) Glaucoma implant
CA1238833A (en) Aqueous humor drainage device

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991904448

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991904448

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991904448

Country of ref document: EP